PTC Therapeutics (PTCT)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Rare Diseasesrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov
Dilution Risk
MEDIUM DILUTION RISKDilution score: 29/100 (MEDIUM), cash runway not available
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: ?% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- PTC Therapeutics to Report Third Quarter 2026 Financial Results on Thursday, Oct. 29, 2026
- 2026 Philadelphia ORBIE Awards Honor Top Technology and Security Executives in Philadelphia
- PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- PTC Completes Acquisition of ST-920 Fabry Disease Gene Therapy
- PTC Therapeutics (PTCT) Could Be 36% Undervalued Following Pipeline Progress
- PTC Therapeutics to Participate in Upcoming Investor Conferences
- PTC Therapeutics Announces New Sephience™ (sepiapterin) Data Reinforcing Broad Patient Benefits Including Sustained Metabolic Control and Diet Liberalization as well as Consistent Favorable Safety Profile
- Wells Fargo Sees Up to 52% Upside in 2 Stocks
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for PTC Therapeutics.
Full PTCT Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.